Dr Klaus Rabe (Lung Clinic Großhansdorf and The University of Kiel, Germany) spoke with touchRESPIRATORY around his post-hoc analysis of the LIBERTY ASTHMA QUEST study (Clinical Trial Identifier: NCT02414854).
The abstract ‘Dupilumab Efficacy in GINA-Defined Difficult To-Treat Type 2 Asthma Patients in the LIBERTY ASTHMA QUEST Study.’ (ABSTRACT NUMBER: 183) was presented at the American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting, February 26-March 1, 2021.
Questions
- What were the aims and design of your post-hoc analysis of the LIBERTY ASTHMA QUEST study data? (0:06)
- What were the findings of this analysis? (3:09)
- What are the implications of these findings for future clinical practice? (3:52)
Disclosures: Klaus Rabe has nothing to disclose in relation to this video.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AAAAI 2021 (Virtual).
